Maximilian J. Mair

Jul 3, 2024 | hal.science | Maximilian J. Mair |Emeline Tabouret |Institut de neurophysiopathologie |Derek Johnson

Article Dans Une Revue (Article De Synthèse) Neuro-Oncology Année : 2024 Radioligand therapies in meningioma – evidence and future directions Origine Fichiers produits par l'(les) auteur(s) hal-04615780 , version 1 (03-07-2024) Maximilian Mair, Emeline Tabouret, Derek Johnson, Erik Sulman, Patrick Wen, et al.. Radioligand therapies in meningioma – evidence and future directions. Neuro-Oncology, 2024, ⟨10.1093/neuonc/noae069⟩.

Jul 3, 2024 | hal.science | Maximilian J. Mair |Emeline Tabouret |Institut de neurophysiopathologie |Derek Johnson

Article Dans Une Revue (Article De Synthèse) Neuro-Oncology Année : 2024 Radioligand therapies in meningioma – evidence and future directions Origine Fichiers produits par l'(les) auteur(s) hal-04615780 , version 1 (03-07-2024) Maximilian Mair, Emeline Tabouret, Derek Johnson, Erik Sulman, Patrick Wen, et al.. Radioligand therapies in meningioma – evidence and future directions. Neuro-Oncology, 2024, ⟨10.1093/neuonc/noae069⟩.

Apr 21, 2023 | nature.com | Maximilian J. Mair |Emilie Le Rhun |Priscilla K Brastianos |Javier Cortés |Hui K. Gan |Michael Weller

Cite this articleMair, M.J., Bartsch, R., Le Rhun, E. et al. Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours. Nat Rev Clin Oncol (2023). https://doi.org/10.1038/s41571-023-00756-zDownload citationAccepted: 21 March 2023Published: 21 April 2023DOI: https://doi.org/10.1038/s41571-023-00756-zShare this articleAnyone you share the following link with will be able to read this content:Sorry, a shareable link is not currently available for this article.